Bracco Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRACCO, and what generic alternatives to BRACCO drugs are available?
BRACCO has forty approved drugs.
There are three US patents protecting BRACCO drugs.
There are thirty-seven patent family members on BRACCO drugs in twelve countries and seventy-four supplementary protection certificates in eight countries.
Drugs and US Patents for Bracco
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bracco | ISOVUE-250 | iopamidol | INJECTABLE;INJECTION | 020327-002 | Oct 12, 1994 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | READI-CAT 2 | barium sulfate | SUSPENSION;ORAL | 208143-001 | Jan 15, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | VARIBAR PUDDING | barium sulfate | PASTE;ORAL | 208844-001 | Oct 14, 2016 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Bracco | CHROMITOPE SODIUM | sodium chromate cr-51 | INJECTABLE;INJECTION | 013993-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bracco
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bracco | ISOVUE-370 | iopamidol | INJECTABLE;INJECTION | 018735-003 | Dec 31, 1985 | 4,001,323 | ⤷ Try a Trial |
Bracco | ISOVUE-370 | iopamidol | INJECTABLE;INJECTION | 020327-004 | Oct 12, 1994 | 4,001,323 | ⤷ Try a Trial |
Bracco | PROHANCE MULTIPACK | gadoteridol | INJECTABLE;INJECTION | 021489-001 | Oct 9, 2003 | 5,846,519 | ⤷ Try a Trial |
Bracco | LUMASON | sulfur hexafluoride lipid-type a microspheres | FOR SUSPENSION;INTRAVENOUS | 203684-001 | Oct 15, 2014 | 5,686,060 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Bracco Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 3137089 | ⤷ Try a Trial |
Israel | 288094 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2020229643 | ⤷ Try a Trial |
Japan | 7357078 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bracco Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1948158 | 1690020-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 |
2932970 | SPC/GB18/041 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
1713823 | 92595 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516 |
1666481 | 17C1031 | France | ⤷ Try a Trial | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.